Overview

Outcome Study to Evaluate Klaricid XL® (Clarithromycin Modified Release) in Patients With Acute Exacerbation of Chronic Bronchitis

Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to evaluate the role of Klaricid XL (clarithromycin modified release) in the treatment of acute exacerbation of chronic bronchitis (AECB) and its impact on improving the quality of life.
Details
Lead Sponsor:
Abbott
Treatments:
Clarithromycin